Sergio Valdés

Dr. Sergio Valdés


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2020 in Scientific Reports
Verified
Journal Article
Open access
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez
SVSergio Valdés
Sergio Valdés
FSF. Soriguer
F. Soriguer
Vendrell JoanVendrell Joan
Vendrell Joan
IUI. Urrutia
I. Urrutia
ACAlfonso Calle-Pascual
Alfonso Calle-Pascual
Our aim was to determine the incidence of type 2 diabetes mellitus in a nation-wide population based cohort from Spain (di@bet.es study). The target was the Spanish population. In total 5072 people older than 18 years,were randomly selected from all over Spain). Socio-demographic and clinical data, survey on habits (physical activity and food consumption) and weight, height, waist, hip and blood pressure were recorder. A fasting blood draw and an oral glucose tolerance test were performed. Determinations of serum glucose were made. In the follow-up the same variables were collected and HbA1c was determined. A total of 2408 subjects participated in the follow-up. In total, 154 people developed diabetes (6.4% cumulative incidence in 7.5 years of follow-up). The incidence of diabetes adjusted for the structure of age and sex of the Spanish population was 11.6 cases/1000 person-years (IC95% = 11.1–12.1). The incidence of known diabetes was 3.7 cases/1000 person-years (IC95% = 2.8–4.6). The main risk factors for developing diabetes were the presence of prediabetes in cross-sectional study, age, male sex, obesity, central obesity, increase in weight, and family history of diabetes. This work provides data about population-based incidence rates of diabetes and associated risk factors in a nation-wide cohort of Spanish population.

1 February 2017 in Thyroid®
Verified
Journal Article
Closed access
SVSergio Valdés
Sergio Valdés
CMCristina Maldonado-Araque
Cristina Maldonado-Araque
ALAna M Lago-Sampedro
Ana M Lago-Sampedro
JLJ. Antonio Lillo
J. Antonio Lillo
EGEduardo Garcia-Fuentes
Eduardo Garcia-Fuentes
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez
Background: The aim of this study was to investigate the national prevalence of thyroid dysfunction in Spain and its association with various clinical, environmental, and demographic variables. Methods: The study included 4554 subjects (42.4% men) with a mean age of 50 years (range 18–93 years), who were participants in a national, cross-sectional, population-based survey conducted in 2009–2010. Data gathered included clinical and demographic characteristics, physical examination, and blood sampling. Thyrotropin, free thyroxine, free triiodothyronine, and thyroid peroxidase antibody (TPOAb) concentrations were analyzed by electrochemiluminescence. Urinary iodine (UI) levels were measured in an isolated urine sample. Results: The prevalence of treated hypothyroidism, untreated subclinical hypothyroidism, and untreated clinical hypothyroidism was 4.2% [confidence interval (CI) 3.6–4.9%], 4.6% [CI 4.0–5.2%], and 0.3% [CI 0.1–0.5%], respectively. The prevalence of total hypothyroidism (including all fractions) was 9.1% [CI 8.2–10.0%]. The prevalence of total hyperthyroidism was 0.8% [CI 0.6–1.1]. A total of 7.5% [CI 6.7–8.3%] of the population tested positive for TPOAbs (≥50 IU/mL). In multivariate logistic regression models, TPOAbs were strongly associated with both hypothyroidism ( p < 0.001) and hyperthyroidism ( p = 0.005), whereas high UI levels (>200 μg/g creatinine) were associated with hypothyroidism ( p < 0.001). The positive association between UI and hypothyroidism remained for both treated ( p < 0.001) and untreated ( p < 0.05) hypothyroidism, whereas it was especially significant for non-autoimmune (TPOAbs negative) forms ( p < 0.001). At UI levels ≥200 μg/g, there was a positive correlation between UI and thyrotropin levels (β = 0.152, p < 0.001) and a negative correlation between UI and free triiodothyronine levels (β = −0.134, p = 0.001). Conclusion: According to the data, a large proportion (10%) of the Spanish population has some evidence of thyroid dysfunction. High TPOAb concentrations were associated with both hypo- and hyperthyroidism, whereas high UI concentrations were associated with hypothyroidism.

13 August 2014 in Obesity
Verified
Journal Article
Open access
PDF file
SVSergio Valdés
Sergio Valdés
CMCristina Maldonado-Araque
Cristina Maldonado-Araque
FGFrancisca García-Torres
Francisca García-Torres
AGAlberto Goday
Alberto Goday
ABAna Bosch-Comas
Ana Bosch-Comas
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez
Objective The aim of this study was to examine possible associations between ambient temperature and obesity in the Spanish population using an ecological focus. Methods The Di@bet.es study is a national, cross‐sectional, population‐based survey of cardiometabolic risk factors and their association with lifestyle. Sample: 5,061 subjects in 100 clusters. Variables: Clinical, demographic and lifestyle survey, physical examination, and blood sampling. The mean annual temperature (°C) for each study site was collected from the Spanish National Meteorology Agency (1971‐2000). Results The prevalence rates of obesity in the different geographical areas divided according to mean annual temperature quartiles were 26.9% in quartile 1 (10.4‐14.5°C), 30.5% in quartile 2 (14.5‐15.5°C), 32% in quartile 3 (15.5‐17.8°C), and 33.6% in quartile 4 (17.8‐21.3°C) (P = 0.003). Logistic regression analyses including multiple socio‐demographic (age, gender, educational level, marital status) and lifestyle (physical activity, Mediterranean diet score, smoking) variables showed that, as compared with quartile 1, the odd ratios for obesity were 1.20 (1.01‐1.42), 1.35 (1.12‐1.61), and 1.38 (1.14‐1.67) in quartiles 2, 3, and 4, respectively (P = 0.001 for difference, P < 0.001 for trend). Conclusions Our study reports an association between ambient temperature and obesity in the Spanish population controlled for known confounders.

9 March 2017 in Obesity
Verified
Journal Article
Open access
PDF file
SVSergio Valdés
Sergio Valdés
CMCristina Maldonado-Araque
Cristina Maldonado-Araque
ALAna M Lago-Sampedro
Ana M Lago-Sampedro
JLJuan Antonio Lillo‐Muñoz
Juan Antonio Lillo‐Muñoz
EGEduardo Garcia-Fuentes
Eduardo Garcia-Fuentes
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez
Objective: To analyze the reference range of thyroid‐stimulating hormone (TSH) in different BMI categories and its impact on the classification of hypothyroidism.Methods: The study included 3,928 individuals free of thyroid disease (without previous thyroid disease, no interfering medications, TSH <10 µUI/mL and thyroid peroxidase antibodies [TPO Abs] <50 IU/mL) who participated in a national, cross‐sectional, population‐based study and were representative of the adult population of Spain. Data gathered included clinical and demographic characteristics, physical examination, and blood and urine sampling. TSH, free thyroxine, free triiodothyronine, and TPO Ab were analyzed by electrochemiluminescence (E170, Roche Diagnostics, Basel, Switzerland).Results: The reference range (p2.5‐97.5) for TSH was estimated as 0.6 to 4.8 µUI/mL in the underweight category (BMI<20 kg/m2), 0.6 to 5.5 µUI/mL in the normal‐weight category (BMI 20‐24.9 kg/m2), 0.6 to 5.5 µUI/mL in the overweight category (BMI 25‐29.9 kg/m2), 0.5 to 5.9 µUI/mL in the obesity category (BMI 30‐39.9 kg/m2), and 0.7 to 7.5 µUI/mL in the morbid obesity category (BMI ≥40). By using the reference criteria for the normal‐weight population, the prevalence of high TSH levels increased threefold in the morbid obesity category (P < 0.01).Conclusions: Persons with morbid obesity might be inappropriately classified if the standard ranges of normality of TSH for the normal‐weight population are applied to them.

12 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLCarlos López-Gómez
Carlos López-Gómez
CSConcepcion Santiago
Concepcion Santiago
SGSara García-Serrano
Sara García-Serrano
EGEva Garcia-Escobar
Eva Garcia-Escobar
Carolina Gutiérrez RepisoCarolina Gutiérrez Repiso
Carolina Gutiérrez Repiso
EGEduardo Garcia-Fuentes
Eduardo Garcia-Fuentes
Background: The effects of different types of fatty acids on the gene expression of key players in the IRS1/PI3K signaling pathway have been poorly studied. Material and Methods: We analyzed IRS1, p85α, and p110β mRNA expression and the fatty acid composition of phospholipids in visceral adipose tissue from patients with morbid obesity and from non-obese patients. Moreover, we analyzed the expression of those genes in visceral adipocytes incubated with oleic, linoleic, palmitic and dosahexaenoic acids. Results: We found a reduced IRS1 expression in patients with morbid obesity, independent of insulin resistance, and a reduced p110β expression in those with lower insulin resistance. A positive correlation was found between p85α and stearic acid, and between IRS1 and p110β with palmitic and dosahexaenoic acid. In contrast, a negative correlation was found between p85α and oleic acid, and between IRS1 and p110β with linoleic, arachidonic and adrenic acid. Incubation with palmitic acid decreased IRS1 expression. p85α was down-regulated after incubation with oleic and dosahexaenoic acid and up-regulated with palmitic acid. p110β expression was increased and decreased after incubation with oleic and palmitic acid, respectively. The ratio p85α/p110β was decreased by oleic and dosahexaenoic acid and increased by palmitic acid. Conclusions: Our in vitro results suggest a detrimental role of palmitic acid on the expression of gene related to insulin signaling pathway, with oleic acid being the one with the higher and more beneficial effects. DHA had a slight beneficial effect. Fatty acid-induced regulation of genes related to the IRS1/PI3K pathway may be a novel mechanism by which fatty acids regulate insulin sensitivity in visceral adipocytes.

28 June 2023 in Clinical Nutrition
Verified
Journal Article
Open access
IGIgnacio Ruiz García
Ignacio Ruiz García
RFRodolfo Matias Ortiz Flores
Rodolfo Matias Ortiz Flores
RBRocío Badía
Rocío Badía
AGAranzazu García-Borrego
Aranzazu García-Borrego
Maria Garcia-FernandezMaria Garcia-Fernandez
Maria Garcia-Fernandez
FBFrancisco J Bermudez-Silva
Francisco J Bermudez-Silva
Oleocanthal and oleacein are olive oil phenolic compounds with well known anti-inflammatory and anti-oxidant properties. The main evidence, however, is provided by experimental studies. Few human studies have examined the health benefits of olive oils rich in these biophenols. Our aim was to assess the health properties of rich oleocanthal and oleacein extra virgin olive oil (EVOO), compared to those of common olive oil (OO), in people with prediabetes and obesity. Randomised, double-blind, crossover trial done in people aged 40-65 years with obesity (BMI 30-40 kg/m2) and prediabetes (HbA1c 5.7-6.4%). The intervention consisted in substituting for 1 month the oil used for food, both raw and cooked, by EVOO or OO. No changes in diet or physical activity were recommended. The primary outcome was the inflammatory status. Secondary outcomes were the oxidative status, body weight, glucose handling and lipid profile. An ANCOVA model adjusted for age, sex and treatment administration sequence was used for the statistical analysis. A total of 91 patients were enrolled (33 men and 58 women) and finished the trial. A decrease in interferon-γ was observed after EVOO treatment, reaching inter-treatment differences (P = 0.041). Total antioxidant status increased and lipid and organic peroxides decreased after EVOO treatment, the changes reaching significance compared to OO treatment (P < 0.05). Decreases in weight, BMI and blood glucose (p < 0.05) were found after treatment with EVOO and not with OO. Treatment with EVOO rich in oleocanthal and oleacein differentially improved oxidative and inflammatory status in people with obesity and prediabetes.